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Abstract: Intranasal delivery of DNA vaccines has become a popular research area 
recently. It offers some distinguished advantages over parenteral and other routes of 
vaccine administration. Nasal mucosa as site of vaccine administration can stimulate 
respiratory mucosal immunity by interacting with the nasopharyngeal-associated lymphoid 
tissues (NALT). Different kinds of DNA vaccines are investigated to provide protection 
against respiratory infectious diseases including tuberculosis, coronavirus, influenza and 
respiratory syncytial virus (RSV) etc. DNA vaccines have several attractive development 
potential, such as producing cross-protection towards different virus subtypes, enabling the 
possibility of mass manufacture in a relatively short time and a better safety profile.  
The biggest obstacle to DNA vaccines is low immunogenicity. One of the approaches to 
enhance the efficacy of DNA vaccine is to improve DNA delivery efficiency. This review 
provides insight on the development of intranasal DNA vaccine for respiratory infections, 
with special attention paid to the strategies to improve the delivery of DNA vaccines using  
non-viral delivery agents. 
Keywords: DNA vaccine; intranasal delivery; infectious diseases; respiratory pathogens; 
adjuvants; mucosal 
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1. Introduction 
Majority of the current licensed vaccines for the prevention of infectious diseases are live-attenuated 
vaccines, inactivated vaccines, or subunit vaccines. Each of them has its pros and cons. The live-attenuated 
vaccines can stimulate both cellular and humoral immune responses, and induce prolonged immunity 
that closely resembles natural infection. However, there are safety concerns associated with the use of 
the live attenuated virus or bacterial vaccines as they may revert to disease causing forms. It is also 
difficult to target multiple viral subtypes or pathogens using live-attenuated vaccines. Inactivated  
and subunit vaccines are safer options as they cannot replicate and do not cause disease. They confer 
protection mainly through humoral immune responses with little or no cellular immunity. The induced 
immunity lasts for a shorter period of time; therefore, supplemental doses are always required. 
In recent years, DNA vaccines have attracted considerable attention as an alternative vaccination 
method against infectious diseases, with the potential to provide broad immune responses similar to  
the live-attenuated vaccines without the risk associated with the replicating micro-organisms. DNA 
vaccine approach relies on the in situ production of target antigens. Plasmid DNA encoding antigenic 
proteins is delivered to the appropriate tissues in the body, leading to the expression of the desired 
antigens, eliciting specific immunogenic responses and thereby inducing immune protection against 
the pathogens. Since the host cells are responsible for antigen production, the natural glycosylation  
and folding of the protein are warranted. Plasmid DNA encoding different bacterial and viral antigens 
have been tested for their immunogenicity and protective efficacy in vivo, confirming their clinical 
potential [1–4]. In addition, DNA vaccines offer several distinct advantages over conventional 
vaccines. The double helical structure of DNA is simple and stable at high temperature, allowing easy 
storage and transportation. Large-scale manufacture of DNA vaccines is convenient and relatively 
cheap. It only requires standard cloning of antigen coding sequence into plasmid vectors, avoiding the 
complex procedures of repeated culture and inactivation of infectious pathogens, or the purification  
of recombinant proteins. Apart from their advantageous physicochemical properties, DNA vaccines 
have the ability to generate the cellular immunity in addition to the humoral immunity. They are also 
highly flexible, encoding several types of genes including viral and bacterial antigens, as well as 
immunological proteins. The advantages of DNA vaccines compared to conventional vaccines are 
summarized in Table 1. 
The field of DNA vaccination is developing rapidly. DNA vaccines are currently approved  
for veterinary use against various infectious diseases [5–8]. However, the results in clinical trials have 
been less encouraging. DNA vaccines are generally safe and well tolerated in human, but the immune 
response is often too low to offer sufficient protection [5,9–11]. In early studies, DNA vaccines alone 
were not able to generate T cell responses at a magnitude that was enough to protect against difficult 
diseases in humans [12,13]. Recent attempts still failed to overcome this problem. A plasmid pTHr 
DNA HIV-1 vaccine candidate evaluation in phase I clinical trials on healthy volunteers showed that  
it had weak immunogenicity in human. No significant HIV-1-specific cell-mediated immune response 
difference was found between vaccine recipients and placebo recipients, in addition to no HIV specific 
antibody production [14]. Another phase I trial of HIV vaccine using DNA prime-virus vector vaccine 
boost strategy on healthy volunteers was proved effective in eliciting T-cell responses but incapable  
of inducing neutralizing antibody activities [15]. In 2012, a human HIV-1 gag DNA vaccine with  
Pharmaceutics 2014, 6 380 
 
 
or without interleukin (IL)-12 and/or IL-15 plasmid cytokine adjuvant was reported to produce poor 
cellular immunogenicity with no vaccine-induced anti-gag humoral immune responses on healthy 
volunteers, which contrasted with the previous findings in macaques [11]. 
Table 1. Advantages of DNA vaccines compared to conventional vaccines. 
Category Characteristics 
Design 
Rapid design 
Vaccine can be developed for multiple agents in a single formulation 
Production 
Rapid and reproducible 
Large-scale production is relatively cheap 
Proteins are produced by host cells to ensure proper folding 
Stability 
Higher stability than proteins or live-attenuated microorganisms 
Ease of storage and transportation 
Safety 
Do not require cultivation of dangerous infectious agents 
No risk of reverting back to virulent forms 
Good safety profile in clinical trials 
Immune responses 
Induce both cellular and humoral immune responses similar to  
live-attenuated vaccines 
Several strategies have been introduced to optimize DNA vaccines [16]. One of them is to enhance 
the DNA delivery efficiency, which is the focus of this review. DNA delivery efficiency is dependent 
on the administration route and the delivery system used. Mucosal surfaces are attractive sites of 
vaccine administration against infectious diseases as they are the portals of entry for many pathogens. 
Vaccination at the mucosal sites where pathogens initiate infections can be more efficacious than 
parenteral administration as invading pathogens may be neutralized at the front lines before generating 
any systemic effect. In particular, intranasal vaccine has been extensively investigated in recent years. 
Vaccination at nasal mucosa can stimulate respiratory mucosal immunity by interacting with the 
nasopharyngeal-associated lymphoid tissue (NALT) where large amounts of local lymphocytes are 
present. Furthermore, intranasal delivery is a needle-free, non-invasive route of administration with  
the possibility of self-administration. Intranasal DNA vaccination has become a promising approach  
in offering immune protection against various pathogens that affect the respiratory system including 
tuberculosis, coronavirus infection, influenza and respiratory syncytial virus (RSV). In this article, the 
current developments of DNA vaccine delivery systems that are specifically designed for intranasal 
administration against respiratory infectious diseases are discussed in detail. 
2. Principles of DNA Vaccines 
2.1. Mechanisms of Action 
Typically, DNA vaccines are administered by intramuscular injection although other administration 
routes including intradermal, subcutaneous, oral and intranasal routes are also investigated. Upon 
administration, somatic cells (e.g., myocytes or keratinocytes) and professional antigen presenting cells 
(APCs) are transfected. As the antigens are expressed intracellularly, both humoral and cell-mediated 
immunity can be activated to offer broad immune protection. The host-synthesized antigens become 
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the subject of immune surveillance in the context of both major histocompatibility complexes (MHC) 
class I and class II molecules of APCs. Antigen expressed APCs then travel to the draining lymph 
nodes where they present the antigenic peptide-MHC complexes and stimulate T cells. Alternatively,  
B cells are activated, initiating the antibody production cascades. The major advantage of DNA 
vaccines is their ability to activate CD8+ T-cells, the cytotoxic T lymphocytes, which are important in 
controlling infections [17]. This action is lacking in inactivated or subunit vaccines. The induction of 
CD8+ T-cells by DNA vaccines can occur in two major ways: (i) direct DNA transfection of the  
APCs such as dendritic cells (DCs); (ii) cross-presentation which occurs when somatic cells such as 
myocytes are transfected with DNA and the expressed antigens are taken up by the APCs, or when  
the transfected apoptotic cells are phagocytosed by the APCs. The mechanisms of DNA vaccines are 
illustrated in Figure 1. 
Figure 1. Mechanisms of action of DNA vaccines. Plasmid DNA encoding antigen  
of interest is transfected into antigen presenting cells (APCs) or somatic cells. Secreted 
antigens activate B cells, leading to antibodies production. APCs are activated by direct 
transfection or cross-presentation (indirect transfer of antigens). APCs then migrate to the 
draining lymph nodes where they present antigenic peptides to T cells via MHC-I  
and MHC-II. 
 
It is interesting to note that immunization may occur rapidly before a DNA vaccine expresses the 
antigens, and antigens expressed in somatic cells may not qualitatively be the major player in eliciting 
immune response. Comparing to the secondary role of somatic cells, bone marrow derived antigen 
presenting cell (APC) activation is an important indicator for successful induction of DNA vaccine 
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immune response, as evidenced by the van Gogh mice experiment [18]. In this study, DNA vaccine 
was delivered into the skin of mouse ears by gene gun. Immune response was produced after the 
inoculation site (i.e., the ear) was rapidly removed after immunization before antigens were expressed, 
indicating that mobile cells are important in elaborating immunity. In another similar study, surgical 
removal of the injected muscle within 10 min of DNA vaccines administration did not affect the 
magnitude or longevity of antibody responses to the encoded antigen [19]. Again, the results 
confirmed the importance of APCs over somatic cells such as myocytes and keratinocytes for eliciting 
immune responses. 
Early studies showed that DNA vaccines are poorly immunogenic with low levels of antigen 
expression. To improve the immunogenicity of DNA vaccines, CpG motifs are commonly employed in 
the construct of the plasmid backbone [20]. Bacterial or viral DNA contains unmethylated CpG motifs, 
whereas in mammalian cells, CpG dinucleotide motifs are rare and are usually methylated [21]. It has 
been demonstrated that the unmethylated CpG motifs have immunostimulatory effect and are 
considered by mammalian cells as pathogen-associated molecular patterns (PAMPs). Unmethylated 
CpG activates innate immune cells through binding to Toll-like receptor 9 (TLR-9), which is 
constitutively expressed in the endosomal compartments of APCs and B cells. Once bound to the DNA 
that is rich in CpG motifs, TLR-9 activates the immune system by initiating pro-inflammatory 
response that result in the production of cytokines such as interferon (IFN)-γ and interleukin (IL)-12. 
However, it was found that TLR-9 deficient mice also responded to DNA vaccines, suggesting that 
TLR-9 may not be the sole mediator of the adjuvant effect [22,23]. DNA vaccines also interact with 
cytoplasmic DNA sensors including TANK-binding kinase 1 (TBK1) [24] and stimulator of IFN genes 
(STING) [25], activating TLR-independent pathways and inducing IFN-γ. These pathways are crucial 
in contributing to the immunogenicity of DNA vaccines. 
Although persistent antigen expression of DNA vaccine is usually expected to provide long-term 
immune protection against infectious diseases, the effect of sustained expression of antigen must be 
carefully examined and controlled. It has been reported that prolonged expression of antigen may lead 
to the switch of type-1 IFN from an antiviral cytokine to an immunosuppressive cytokine [26], or may 
deplete the pool of memory T cells [27]. 
To evaluate the efficacy of DNA vaccine in humans, serum antibody titer or the enzyme-linked 
immunoSpot (ELISpot) assays are the commonly employed methods to measure the immunogenic 
response, although the induction of antigen-specific immune effectors by an immunization process 
does not imply that these antibodies or cytokines represent surrogates or correlates of vaccine efficacy. 
In early stage of vaccine development, in vitro serum antibodies and ELISpot assays are the direct 
detectable indicators of the clinical potential of a vaccine formulation. At later stage of development, 
morbidity and mortality (especially the improvement of survival rate after vaccination) in animals upon 
target pathogen challenge is a more certain way to confirm the protective efficacy of vaccines [28,29],  
as the ultimate goal of vaccine is to prevent the targeted disease. The efficacy of vaccine such as 
influenza vaccine could be monitored in human during subsequent influenza epidemic season [30,31] or 
challenged with a controlled influenza virus [32]. However, some lethal virus challenge studies are 
difficult to conduct directly on human. Hence, the measurement of antibodies production and immune 
responses in humans remain the most direct way to assess vaccine efficacy. Longer study is required to 
investigate if the vaccine is indeed able to prevent disease. 
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2.2. Safety of DNA Vaccines 
Safety is always a primary concern with any vaccine products. DNA vaccines are generally considered 
to be safer than conventional vaccine approaches as they lack the risk of reversion to a disease causing 
state or secondary infection. Similar to other gene therapy, the major safety issue related to DNA 
vaccines is the risk of integration of the plasmid DNA into the host genome, causing insertional 
mutagenesis, which may lead to the inactivation of tumour suppressor genes or activation of oncogenes, 
resulting in devastating adverse effects. According to preclinical and clinical studies, there is little 
evidence of genomic integration following DNA vaccines administration, and the risk of integration is 
found to be significantly lower than the spontaneous mutation rate [33–36]. 
Another safety issue of DNA vaccines is related to the development of anti-DNA immune responses. 
Animal studies showed that there is no increase in anti-nuclear or anti-DNA antibodies after  
DNA vaccination. In clinical trial studies, signs and symptoms of autoimmunity, and the markers  
of autoimmunity are sometimes monitored in the human subjects. There has been no evidence that 
autoimmunity is associated with DNA vaccines [5,37–39]. It has been suggested that proper 
purification of E. coli can effectively prevent pathogenic anti-DNA antibody production [2,40]. 
Antibiotic resistance is another issue related to DNA vaccines. Typically, large-scale manufacture of 
plasmid DNA involves the use of antibiotic-resistant marker. There is a safety concern that resistance 
to the same antibiotic might be introduced. In response to this issue, antibiotic-resistance genes in 
DNA vaccine should be restricted to those that are not used to treat human infections. Alternatively, 
the use of antibiotic-resistance genes should be avoided completely [41]. Another concern of DNA 
vaccines is the development of tolerance to the encoded antigen, which appears to be age-related. 
Newborns have immature immune system and are more likely to develop tolerance rather than 
protection when exposed to foreign antigens. In contrast, immunity instead of tolerance occurred when 
DNA vaccines are administered to young animals [42–44]. 
In recent years, there has been an increasing concern that vaccination in general may induce 
harmful systemic inflammation, which may lead to increase of cardiovascular risk [45–49]. DNA 
vaccine is still considered as a relatively new approach to vaccination but its potential to induce 
systemic inflammation must not be overlooked. It was reported that little or no local inflammatory 
infiltration was observed at the DNA vaccine injection site, especially after the acute effects of the 
vaccination have disappeared [9]. The first clinical trial of a DNA-based vaccine for HIV-1 infection 
was published in 1998 in 15 asymptomatic HIV-infected patients who were not using antiviral drugs. 
The immunization was well tolerated with neither local, systemic reaction nor laboratory abnormalities 
were detected after three doses of vaccines [38]. In addition, no patient developed anti-DNA antibody 
or muscle enzyme elevations. No consistent change of CD4+ or CD8+ lymphocyte counts occurred.  
Another early experiment conducted on pigs showed that electroporation of DNA vaccines was more 
efficient in enhancing immune response, but also stimulated inflammatory response and accompanying 
cellular infiltration, whereas the conventional intramuscular injection of DNA vaccines only showed 
low gene expression and low inflammatory cell infiltration [50]. It was suggested that improved 
antigen presentation was one of the possible mechanisms by which increased inflammatory cell 
infiltration may enhance immune responses to DNA vaccines delivered with electroporation. However, 
the long-term safety effect was not investigated. 
Pharmaceutics 2014, 6 384 
 
 
Overall, many recent preclinical studies and clinical trials have indicated that DNA vaccines are 
generally well tolerated with good safety profile, and no systemic inflammation was reported [11,14,51–54]. 
Nonetheless, DNA vaccines are relatively new vaccination approaches and yet to be approved in 
human use, the long term safety of their uses must be thoroughly evaluated for routine prophylactic 
and therapeutic use in human, especially when new delivery systems or adjuvants are introduced into 
the formulation. 
3. Intranasal Vaccines 
Conventional vaccines are usually administered by parenteral injections which mainly target the 
systemic immune system, eliciting only weak mucosal immune response. When the vaccines are 
delivered directly to the mucosal site, mucosal immune response can be more efficiently potentiated. 
In particular, nasal mucosa has attracted considerable attention as the site of vaccination in recent 
years, including DNA vaccines, due to several distinct advantages. However, there are also some 
formidable barriers that need to be overcome to allow successful development of intranasal  
DNA vaccines. 
3.1. Intranasal Route of Administration 
The intranasal route of drug administration has been frequently used to treat local conditions such 
as nasal congestion and allergy. Intranasal administration is characterized by easy administration, rapid 
onset of action and avoidance of first-pass metabolism. The needle-free administration route is  
non-invasive and can avoid the risk of spreading blood-borne infections, which is a particular problem 
in developing countries. These desirable features lead to the exploration of the systemic delivery of 
polar drugs or biomolecules including vaccines that are not feasible in other administration routes. 
Intranasal vaccination has been investigated for over a decade. The majority of currently available 
vaccines are administered by intramuscular, subcutaneous or intradermal injection. Although these 
parenteral routes of administration are effective in inducing systemic immune responses, they are 
ineffective in inducing local immunity at mucosal sites. As many as 70% of pathogens infect human 
through the mucosal surfaces [55]. Mucosal vaccination could provide better protection than injectable 
vaccines against infectious diseases by inducing both systemic and mucosal immunity [56,57]. Since 
the strongest immune response is usually induced at the vaccination site and the adjacent mucosal 
sites, intranasal immunization is able to elicit protective immune response effectively in the lungs  
and the upper respiratory tract [58]. Nasal mucosa appears to be an appropriate site of vaccine 
administration against respiratory infectious diseases, not only because the nasal cavity is the first site 
of contact with inhaled macromolecules and a common site of infection by respiratory pathogens,  
it can also stimulate respiratory mucosal immunity by interacting with the NALT. Current, licensed 
intranasal vaccines include FluMist®, a live-attenuated vaccine that targets influenza types A and B [59]; 
and NASOVAC®, a live-attenuated vaccine that targets H1N1 influenza virus [60]. Apart from  
live-attenuated vaccine, intranasal route of administration is also favorable to protein-based vaccination, 
as evidenced by many studies including the intranasal pneumococcal protein immunization against 
pneumonia [61], and a recent study on the intranasal respiratory syncytial virus (RSV) vaccine based 
on a recombinant fusion protein [62]. With the success of intranasal live-attenuated virus vaccine and 
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the promising effect of protein-based vaccine, it is highly plausible that DNA vaccines can adopt the 
same delivery route to achieve efficient immunization. 
3.2. Mechanisms of Nasal Mucosal Immune Protection 
It is well established that mucosal vaccination can induce humoral and cell-mediated immune 
response systemically as well as at mucosal sites [56,57]. Immune response induced by mucosal 
vaccination is mainly initiated at specific mucosa-associated lymphoid tissue (MALT). The MALT 
lining the nasal cavity is known as the nasopharyngeal-associated lymphoid tissue (NALT), which 
include the Waldeyer’s ring of tonsils, adenoids and a collection of isolated subepithelial lymphoid 
follicles [63]. The NALT is rich in immunocompetent cells, including B cells, T cells and phagocytic 
APCs such as macrophages and DCs [64]. In addition, the overlying epithelium of mucosal follicles 
forms a specialized cell layer. These cells have microfolds on their apical surface and are known as 
microfold cells (M cells). M cells play a crucial role in the initial phase of induction of mucosal 
immune responses. Therefore, M cell targeting is an important strategy to achieve mucosal  
immunity [65,66]. M cells are efficient in taking up particles from the epithelial surface, transporting 
them across the cells and releasing them to the underlying extracellular space. This process is known 
as transcytosis. At their basal surface, the cell membrane of M cells is extensively folded around the 
underlying immune cells including B cells, T cells and APCs, which take up the particles released 
from M cells and process them for antigen presentation. The initiation of mucosal immune response is 
summarized in Figure 2. 
Figure 2. The initiation of mucosal immune response. Particles are taken up by M cells 
and transported to the underlying immune cells through transcytosis. Dendritic cells (DCs) 
at mucosal site may migrate to the nearest draining lymph node to present antigen to T cells. 
 
Upon B cells activation following nasal vaccination, the production of antigen-specific secretory 
immunoglobulin A (sIgA) is triggered. sIgA is a critical component in the mucosal immune system.  
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It is protease resistant, and can effectively bind and neutralize pathogens and their toxic products on 
the nasal mucosa surface despite the protease rich environment, thereby preventing the pathogens from 
breaching the mucosal barrier [67]. Local immunoglobulin G (IgG) production is also detected  
after mucosal vaccination [68] and partly contributes to the neutralization of pathogens. However, IgG 
concentration is around 30–100-fold lower than that of the sIgA due to its susceptibility to protease 
degradation [56]. Indeed, sIgA provides the first barrier to pathogens invasion, so induction of potent 
sIgA response is an important goal of mucosal vaccination. In addition, nasal immunization can also 
result in the production of serum IgA and serum IgG, which can potentially neutralize pathogens  
that enter the mucosa and prevent systemic spread. When the DCs at the mucosa are presented  
with antigens, the activated cells may migrate to the proximal draining lymph node and disseminate 
immune responses to other sites of the body. Apart from the humoral immune response, cell-mediated 
immune response is also induced after mucosal vaccination. Although the cytotoxic T cells in the 
mucosal tissues may not prevent pathogen entry, they are crucial for the clearance of pathogens [56]. 
Overall, cells of NALT are involved in the regulation of both humoral and cell-mediated immune 
responses locally and also systemically, offering a broad immune response. Since the nasal mucosa is 
an important portal of entry for respiratory pathogens, the nasal route has become attractive for the 
administration of vaccines by reinforcing the nasal mucosal immune response. 
3.3. Barriers to Intranasal DNA Vaccines 
The defense mechanism of the nasal cavity presents a significant barrier to the entry of pathogens 
and potentially harmful substances; however, it has also become an important barrier to intranasal 
DNA vaccines. The nasal mucosa, which constitutes the outmost layer of the nasal passage, consists 
mainly of ciliated columnar cells, non-ciliated columnar cells, goblet cells and basal cells.  
The proportions of these cells vary in different regions of the nasal cavity. Nasal mucus, which is 
produced by goblet cells and submucosal glands, provides a protective physical barrier to foreign 
materials. It is a highly viscous, gel-like heterogeneous mixture that contains glycoproteins, enzymes, 
immunoglobulins, salts, proteins and lipidic components [69]. DNA vaccines that are administered to 
the nasal cavity have a propensity to be trapped by the nasal mucus, leading to enzymatic degradation. 
The effect of mucus depends on its viscosity and pore size, which affect the diffusivity of agents 
delivered to mucosal surfaces. In addition, the entrapped DNA vaccines may also be removed by the 
mucociliary action of the ciliated cells that drives the overlying mucus layer continuously towards  
the nasopharynx, clearing the mucus from the nasal passage, resulting in short residence time at the 
mucosal surface. Another challenge of intranasal vaccine is that the vaccine formulation may be 
diluted in mucosal fluids, and bulk fluid may limit effective deposition onto the epithelium of the 
mucosal system. 
To overcome these barriers, a safe and efficient DNA delivery system must be developed. Ideally 
such delivery system should target the mucosal APCs for antigens processing that lead to specific B 
and T cell activation. The ultimate goals of DNA delivery systems are to facilitate the uptake of DNA 
to the target tissues and cells, protect DNA from enzymatic degradation, increase the residence time of 
the formulation in the nasal cavity, enhance the expression of the antigens and to increase the immune 
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response without compromising safety. The different DNA vaccine delivery systems currently being 
investigated for intranasal administration are discussed in detail in Section 5. 
3.4. Potential Risks of Intranasal Vaccine to the Central Nervous System 
Despite the numerous merits of intranasal immunization, the potential hazard of nasal vaccines 
must not be overlooked. The concern of the safety of intranasal vaccination was raised after an 
intranasal inactivated influenza vaccine called NasalFlu, developed by Berna Biotech, was found to be 
associated with Bell’s palsy, a temporary neurological paralysis of one side of the face [70].  
NasalFlu consists of influenza virosomes which are formulated to contain hemagglutinin (HA) and 
neuraminidase (NA) antigens, as well as heat-labile enterotoxin (LT) from E. coli as mucosal adjuvant. 
Since parenteral administration of inactivated influenza vaccine did not confer an increased risk of 
Bell’s palsy, nor the natural influenza virus infection, it was soon concluded that adjuvant LT from  
E. coli. was the culprit of these cases. For this reason, FluMist® and NASOVAC®—both are intranasal 
live-attenuated influenza vaccines without enterotoxin as adjuvants—do not appear to confer an 
increased risk for this condition. 
Understanding the pathogenesis of the Bell’s palsy that was connected to NasalFlu has become  
an important research focus for vaccine development. Following intranasal administration in mice, 
enterotoxins were found in the olfactory nerve and the olfactory bulb for an extended period. Since  
the olfactory epithelium is the only part of the central nervous system (CNS) that is exposed to the  
external environment, drugs and nanoparticles, including intranasal vaccines, may bypass the blood 
brain barrier and enter the CNS through olfactory transmission. There is a reason to concern the 
neurotoxic effects of vaccine containing enterotoxin adjuvant for intranasal administration. While the 
nasal delivery of neuronal-binding LT-derived adjuvants is inadvisable [71], other toxin-derived 
adjuvants such as cholera toxin-derived CTA-DD and double mutant cholera enterotoxin (CT) are 
claimed to be safe and effective adjuvant candidates without causing any inflammation or CNS 
toxicity [72,73]. Nevertheless, thorough evaluation must be performed with the use of toxin derivatives 
as intranasal vaccine adjuvants. Tremendous efforts are now focusing on the development of 
alternative adjuvants with better safety profile. 
4. Clinical Applications of DNA Vaccines against Respiratory Infections 
Mankind has been haunted by respiratory infectious diseases for aeons. They have created public 
health concerns since ancient times. With the emergence of new or drug-resistant strains, it is becoming 
a challenge to protect the public from infections using conventional vaccine methods. DNA vaccines 
have huge potential for the prevention of respiratory infections due to their ability to offer broad 
immunity, the relatively rapid process of designing new DNA vaccine construct and the possibility of 
large-scale production in a short period of time. In this section, four pathogens that cause severe 
diseases in the airways are highlighted, including tuberculosis, coronavirus, influenza and respiratory 
syncytial virus, with a brief discussion of current DNA vaccine development against these infections. 
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4.1. Tuberculosis (TB) 
Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis which is 
transmitted by respiratory aerosols. TB has become a major public health problem that threatens the 
progress made in TB care and control in the world. The only TB vaccine currently available is an 
attenuated strain of Mycobacterium bovis, Bacillus Calmette-Guérin (BCG), developed in the 1920s. 
However, its efficacy against adult pulmonary TB remains controversial [74]. With the emergence of 
drug-resistant TB and increasing rates of HIV/AIDS and TB co-infection, a new effective TB vaccine 
is urgently in need. Effective protective immunity to Mycobacterium tuberculosis requires cell-mediated 
immune responses, including both CD4+ and CD8+ T cells [75–77]. Since DNA vaccines have the 
ability to induce strong cellular immunity, it has become an attractive vaccine approach against TB. 
The first two studies that reported promising protective effect with DNA vaccine against  
tuberculosis were conducted in mice using plasmid DNA encoding antigen 85A (Ag85A) of  
Mycobacterium tuberculosis [78] and the 65 kDa heat-shock protein of Mycobacterium leprae  
(hsp65) [79]. Other different antigens such as Ag85B ESAT-6, IL-23, MPT64, PstS-3 and other fusion 
proteins have also been explored as DNA vaccines against tuberculosis [80–85]. Most of these DNA 
vaccines encode mycobacterial proteins that are either secreted in mycobacterial culture filtrate or 
exposed on the mycobacterial cell-wall surface. 
4.2. Coronaviruses (CoV) 
Coronaviruses (CoV) are potentially lethal pathogens, characterized by the presence of spike 
proteins on the viral surface. Two new strains, severe acute respiratory syndrome CoV (SARS-CoV) 
and Middle East respiratory syndrome CoV (MERS-CoV), have been identified. Both of them could 
cause acute respiratory distress syndrome (ARDS) and are associated with high mortality rates [86]. 
CoV vaccines have historically exhibited poor capacity for cross-protection [87], the development of 
safe, broad spectrum and effective vaccines that can be rapidly made available during an emerging 
epidemic is required. Currently, there are no approved vaccines for human CoV infections, and most  
of the studies have focused on the SARS-CoV. Spike and nucleocapsid proteins, which are the 
immunodominant CoV proteins, are the antigens of interest for vaccine development [88,89]. DNA 
vaccines that encode nucleocapsid protein induced strong cell-mediated immunity but are not protective 
after high titer of viral challenge [90,91]. In addition, nucleocapsid DNA vaccine could induce 
delayed-type hypersensitivity even in the absence of an antibody response. This effect was not observed 
with spike protein DNA vaccines. 
4.3. Influenza 
Influenza is caused by orthomyxoviruses which are RNA viruses that affect mainly the upper 
respiratory tract. In recent years, zoonotic or variant influenza has become a serious threat to human 
health, including the avian influenza virus H5N1 and H9N2, and the swine influenza virus H1N1 and 
H3N2. Although these animal viruses are distinct from human influenza viruses and do not usually 
transmit between humans, they may still occasionally infect humans and cause severe pneumonia and 
even death. Furthermore, if such a virus acquired the capacity to spread easily among people, it could 
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start an epidemic or even a pandemic [92,93]. To protect the populations from influenza infection, 
highly effective, broad-spectrum influenza vaccines that could be prepared rapidly are in demand. 
Current influenza vaccines mainly target the induction of antibodies against the viral glycoproteins, 
particularly surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Antibodies to HA 
neutralize the infectivity of the virus while antibodies to NA prevent the release of the virus from the 
infected cells. Apart from surface glycoproteins, internal proteins such as nucleoprotein (NP) and 
matrix protein (M1), as well as the ion channel protein (M2), which are highly conserved between and 
within different subtypes, have also become very attractive target antigens for vaccines to provide 
broad, cross-strain protection [94,95]. 
DNA vaccines can potentially solve the mismatch problem by shortening the lag time [96], which is 
particularly useful when facing influenza pandemic. In addition, the strategy of combined immunization 
with DNA vaccines encoding surface protein (e.g., HA) and internal protein (NP and M1) could offer 
better protection against influenza virus than single DNA vaccine alone in mice and ferrets [97–100]. 
With the success of DNA vaccines in various animal models, several phase I & II clinical trials on 
DNA vaccine against influenza have been being carried out. Results so far have been encouraging, 
demonstrating both safety and immunogenic response in human [32,52,101]. 
4.4. Respiratory Syncytial Virus (RSV) 
Respiratory syncytial virus (RSV) is a single stranded RNA pneumovirus which belongs to 
Paramyxoviridae family. It accounts for one of the leading pathogeneses of lower respiratory tract 
infections and hospitalization in infants and young children [102], as well as the elderly and high-risk 
population [103]. Immunity against RSV is dependent on the induction of antibody responses.  
In addition, CD8+ T cells responses have been shown to reduce disease severity [104]. Although 
maternal antibodies appear to protect infants against infection, their amount gradually decreases within 
the first few months of life. Human RSV lacks an approved vaccine or an antiviral therapy. To prevent 
infant and childhood infection, vaccine should be able to induce immune responses rapidly after birth. 
This could be a challenging task because the immune system at the first few months of life is 
immature, and the persistence of maternal antibodies may limit the induction of infant antibodies 
responses. Three RSV proteins, namely the fusion (F) protein, attachment glycoprotein (G) and matrix 
protein (M2), are the leading candidates for RSV vaccine development [105–111]. 
5. DNA Vaccine Delivery System for Intranasal Administration 
Delivery is one of the major barriers to DNA vaccine. Administration of naked DNA is usually 
inefficient with only a small fraction of DNA being taken up by the cells and subsequently  
expressed [112]. This is because DNA is a negatively charged, hydrophilic macromolecule; it is 
incapable of crossing the biological membrane unassisted. Therefore, a safe and efficient DNA 
delivery system is sometimes employed as adjuvant to facilitate efficient cellular uptake of DNA 
vaccines, promote DNA release inside the cells, induce high level of antigen expression and hence 
immune responses. Physical method such as gene gun, also known as the particle-mediated epidermal 
delivery, has been studied to deliver DNA to the skin [101,113–115]. Gold beads coated with DNA 
vaccines are discharged directly into the cytoplasm and nuclei of skin cells. This method of delivery 
Pharmaceutics 2014, 6 390 
 
 
has enjoyed some success, but is not applicable for intranasal administration. Considerable efforts  
have been made to improve the efficacy by developing effective DNA delivery systems for  
intranasal vaccines. Formulation of DNA vaccines in synthetic non-viral vectors such as polymeric 
nano-/micro-particles and liposomes has been reported to increase the uptake of plasmid DNA by cells, 
increasing immunogenicity in animal models and humans. Additional adjuvants may also be used to 
further improve the immunogenicity of these delivery systems. 
5.1. Cell-Specific Targeting 
The elicitation of immune responses of DNA vaccines mainly relies on professional APCs that 
present antigens to both B cells and T cells. To ensure good immune response, the DNA vaccine 
delivery systems should be able to target APCs. In addition, M cells in NALT, which is a major site  
of pathogen entry, are also a target of DNA vaccine. 
APCs are a heterogeneous group of immunocompetent cells that mediate immune response by 
processing and presenting antigens to the T cells. T cells recognize only antigenic peptide fragments 
on the surface of APCs through the T cell receptors. Helper T cells recognize antigen in association 
with class II MHC proteins, whereas cytotoxic T cells recognize antigen in association with class I 
MHC proteins. An additional co-stimulatory signal is then produced by the APCs, leading to the 
activation of T cells. Non-professional APCs lack the co-stimulatory signaling, and therefore do not 
simulate T cells sufficiently. There are three types of professional APCs, namely DCs, macrophages 
and B cells. Among them, DCs have the broadest range of antigen presentation and are considered as 
the most efficient cells for induction and regulation of immune responses. They play a central role in 
bridging the innate immune system with the adaptive immune system [116–118]. To achieve efficient 
DNA vaccination, it is logical to target the plasmid DNA to DCs where the encoded antigen could be 
expressed endogenously. 
DCs express a large number of surface receptors such as C-type lectin receptors (CLRs) and TLRs, 
which are engaged in the recognition of pathogens. It has been reported that targeting antigens  
to receptors on DCs can significantly enhance immune responses [119]. These receptors could be 
exploited for DNA vaccine targeting with the aid of antibodies or natural ligands. In particular, CLRs 
are endocytic receptors which recognize carbohydrate structures that resemble pathogen cell-wall 
components. They are responsible for internalizing pathogens. One of the most commonly studied 
receptors for vaccine targeting is the DC C-type lectin receptor 205 (DEC-205) which is specifically 
expressed on DCs. However, ligands for DEC-205 have yet to be identified. Several studies have 
demonstrated the employment of anti-DEC-205 antibodies to achieve DC targeting for DNA vaccines, 
including intranasal immunization [120–122]. Another identified DC-specific target is C-type lectin 
domain family 9 member A (CLEC9A). Activation of CLEC9A leads to the stimulation of antibody 
production [123]. Alternatively, DCs could be targeted by using the natural ligands to the mannose 
receptors [124]. However, the effectiveness of these targeting components in mucosal vaccines 
remains to be investigated. 
There are also several molecules being investigated to target APCs in general. One of the most widely 
studied molecules is the Flt3 ligand. Flt3 ligand is a growth factor that stimulates the proliferation  
of hematopoietic cells. It binds to the fms-like tyrosine kinase receptor Flt3. Flt3 expression is,  
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in hematopoietic tissue, restricted to CD34+ progenitors, including DC progenitors. In vivo treatment 
of Flt3 ligand is found to up-regulate the number of DCs, but not their activation [125,126]. 
Furthermore, Flt3 ligand treatment could also enhance immune response when delivered via the 
mucosal route [127]. It has been reported that when plasmid DNA encoding Flt3 ligand was  
co-administered with plasmids encoding protein antigens, effective immune responses were  
induced [128]. In addition to its APCs targeting ability, Flt3 ligand is an efficient and safe mucosal 
adjuvant that facilitated expansion of DCs following nasal administration [129,130]. 
As discussed in Section 3.2, improving M cells uptake is another strategy to enhance vaccine immunity. 
Effective mucosal immunity often correlates with the uptake of antigen by mucosal inductive tissues, 
such as NALT in the upper respiratory tract following intranasal immunization. Since M cells are 
responsible for antigen sampling on the mucosal surface for eventual antigen presentation to mucosal 
B and T cells, targeting of vaccines to M cells can be an effective method to achieve strong immune 
response. Particle size is an important parameter for M cell uptake. A number of studies have been 
conducted to identify the optimal particle size for cellular uptake of the mucosal system. Some studies 
suggest that particle size of less than 1 μm is optimal for oral vaccine delivery for Peyer’s patch M cell 
uptake [131–133]. Another NALT nanoparticle uptake study also suggested that particles with  
sub-micron size are optimal for mucosal M cells uptake [134]. It is generally accepted that NALT  
M cells can uptake nanosized particles rapidly with no definite size range being established [135]. 
Apart from cellular uptake, particle size also affects the kinetics of lymphatic drainage. It appears that 
nanoparticles less than 200 nm are more readily transported by the draining lymph compared to  
larger particles [136]. 
Apart from controlling particle size to achieve specific targeting passively, inclusion of targeting 
ligand could also increase uptake by M cells [133,137]. A number of pathogens including reovirus [138], 
Salmonella typhimurium [139] and Mycobacterium tuberculosis [140] target M cells as a mode of 
entry into the host. By identifying the key molecules expressed by these pathogens that are crucial for 
their invasion, it would be extremely helpful to design an effective delivery system for M cells 
targeting [141]. One example is related to reoviruses which target M cells using their surface protein 
sigma-1 (σ1). In this regard, Wu et al. reported an M cell targeting DNA vaccine delivery system 
consisting plasmid DNA and the recombinant protein σ1 as targeting ligand which was covalently 
attached to poly-L-lysine (PLL) for intranasal vaccination in mice. The results showed significant 
mucosal sIgA production as well as enhanced cell-mediated immunity [65]. Other ligands such as Co-1 
peptide [142], Claudin 4 targeting peptide [134,143] and M cell specific monoclonal antibody  
(NKM 16-2-4) [144] have been investigated for M cell targeting in mucosal protein vaccine, with the 
potential to be explored for mucosal DNA vaccine delivery. However, mucosally induced tolerance may 
develop with M cell targeting delivery system. Following nasal administration of protein σ1 
genetically conjugated with ovalbumin, systemic unresponsiveness was induced instead of mucosal 
IgA immunity [145]. Therefore, special attention must be paid with the development of M cell 
targeting delivery system. 
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5.2. Polymers 
High versatility is one of the attractive features of polymer-based DNA delivery systems. Cationic 
polymers can form complexes (polyplexes) with nucleic acids through electrostatic interaction. Polymer 
synthesis is relatively cheap and is easy to scale-up. Particle size and surface properties of polymeric 
particles can be controlled by using different polymers and fabrication methods in order to optimize 
their cellular uptake and transfection efficiency. The polymeric particles can also be modified to 
include specific function groups or ligands to enhance immune responses. 
5.2.1. Polyethylenimine (PEI) 
Polyethylenimine (PEI) (Figure 3) is one of the early generation polymers being investigated for 
gene delivery. It has high transfection efficiency and is frequently regarded as the gold-standard of 
non-viral gene delivery vectors. PEI has high pH buffering capacity, which allows its cargo to  
escape from endosomal entrapment via a mechanism known as “proton sponge hypothesis” [146]. 
Transfection efficiency of PEI depends on its molecular weight and the level of branching. Shim et al. 
described the use of a simple method to prepare PEI (25 kDa)–DNA complexes for vaccine  
delivery [147]. Plasmid DNA encoding SARS-CoV spike protein without transmembrane domain was 
employed in the study. Mice that were immunized intranasally with the PEI–DNA vaccines produced 
significantly higher systemic spike protein specific IgG and mucosal secretory IgA in the lung 
compared to those immunized with naked DNA. Furthermore, cellular immune responses were 
detected with an improvement of specific T cell responses. In another study, Torrieri-Dramard et al. 
demonstrated the utilization of PEI (in vivo-jetPEI®) as DNA vaccine carrier for intranasal 
administration [148]. Plasmid DNA encoding HA from influenza A viruses was used. The intranasal 
administration of the PEI/DNA vaccines induced cellular and humoral immune response capable of 
providing protective immunity against a divergent virus of H5N1 subtype in mice. The protection 
could be further improved by including the plasmid DNA encoding NA. 
Although PEI appeared as a promising vector for gene delivery including DNA vaccines, the cationic 
PEI is highly charged and non-biodegradable, and it often encounters toxicity problems which cannot 
be ignored. In this regard, many groups are developing low toxic or biodegradable PEI derivatives for 
gene delivery application. Mann et al. has developed a PEI derivative, deacylated PEI (dPEI), as DNA 
vaccine delivery agent [149]. dPEI is a nearly fully hydrolysed linear PEI with 11% additional  
free protonatable nitrogen atoms, enabling more efficient binding with DNA, reduced toxicity and  
high transfection efficiency. It is an effective DNA vaccine carrier for pulmonary delivery to elicit 
both systemic and mucosal immune responses, and offers protection against influenza challenge in 
vaccinated mice. This system has a potential to be exploited for intranasal administration. 
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Figure 3. Chemical structures of Polyethylenimine (PEI) (a,b), Chitosan (c) and  
Poly(lactic-co-glycolic acid) (PLGA) (d). 



5.2.2. Chitosan 
Chitosan (Figure 3) is a natural polysaccharide that has been frequently studied for drug delivery.  
It is derived from chitin which is found abundant in crustacean. It is biodegradable and biocompatible 
with low toxicity [150,151]. The properties of chitosan can be tuned by changing its molecular weight 
and degree of deacetylation. Because of its cationic nature, chitosan has strong binding affinity with 
nucleic acids, making it a suitable candidate for DNA delivery agent. In addition, chitosan and its 
derivatives are found to display strong mucoadhesive property, making them particularly suitable to 
facilitate intranasal delivery [152–154]. Moreover, chitosan was also reported to have an immunostimulating 
effect, such as increasing the accumulation and activation of macrophages, promoting resistance to 
infections by cytokines, and enhancing cytotoxic T cell response [155,156]. 
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A number of studies have described the use of chitosan nanoparticles to deliver DNA vaccine 
formulation for intranasal administration. Kumar et al. reported the exploitation of chitosan 
nanoparticles to deliver DNA vaccine against acute respiratory syncytial virus (RSV) infection [156]. 
A cocktail of plasmid DNA encoding a number of RSV antigens was used to complex with chitosan to 
form nanoparticles. Following the nasal vaccination in mice, high levels of serum IgG and mucosal 
IgA antibodies, as well as cytotoxic T cells responses were induced. There was also an elevated  
lung-specific production of IFN-γ with antiviral action. A single dose of DNA vaccine was able to 
decrease the RSV titers by 100-fold on primary infection. Similar study was performed by another 
group who described the use of chitosan nanoparticles to deliver plasmid DNA encoding a T cell 
epitope from the M2 protein of RSV [157]. It was found that intranasal administration of the 
formulation in mice induced specific cytotoxic T cell response that was comparable to those induced 
via intradermal immunization. Following RSV challenge of the nasal immunized mice, the virus load 
in lungs was significantly reduced. 
In a recent study, Raghwanshi et al. investigated a sophisticated DC targeted chitosan nanoparticle 
system for nasal DNA immunization against SARS-CoV [122]. The chitosan nanoparticles were 
surface functionalized with ligands to achieve DC selective targeted delivery. DEC-205 receptor is  
C-type lectin receptor found in DCs for recognition and uptake of pathogens. The authors developed a 
bifunctional fusion protein (bfFp) vector which consists of truncated core-streptavidin fused with  
anti-DEC-205 single chain antibody. The core-streptavidin arm of the fusion protein binds with 
biotinylated chitosan nanoparticles while anti-DEC-205 scFv imparts targeting specificity to DC 
DEC205 receptor. Plasmid DNA encoding nucleocapsid protein of SARS-coV was loaded into the 
chitosan nanoparticles. Following intranasal administration of the DC targeted nanoparticles in mice, 
the levels of mucosal IgA and systemic IgG against nucleocapsid proteins were significantly enhanced, 
whereas no mucosal and systemic immune responses were detected when the naked plasmid DNA was 
intranasally administered. The results showed that such DC targeting delivery system could be a 
promising strategy for low-dose nasal DNA vaccines. 
To enhance the transfection efficiency of chitosan for intranasal administration, thiolated chitosan 
derivative has been introduced. Thiolated chitosan derivative has strong mucoadhesive properties due 
to the formation of disulphide bonds between thiol groups of the modified polymer and cysteine-rich 
subdomains of glycoproteins in the mucus layer, leading to an improvement in mucoadhesion of up to 
140-fold when compared to unmodified chitosan [158]. Improved and sustained gene expression could 
be achieved both in vitro and in vivo with thiolated chitosan derivative [159]. This technology has a 
huge potential to be adopted for intranasal DNA vaccine delivery. 
5.2.3. Poly(lactic-co-glycolic acid) (PLGA) 
Poly(lactic-co-glycolic acid) (PLGA) (Figure 3) is a synthetic biodegradable copolymer that has 
been extensively investigated for the delivery of different therapeutic agents including proteins and 
nucleic acids [160]. Due to its biocompatibility and excellent safety profile, PLGA is approved by the 
FDA in various drug delivery systems for human use. Since the degradation rate of PLGA can be 
adjusted by modifying the molecular weight of the polymer and the lactic acid to glycolic acid ratio, 
the rate of drug release can also be controlled accordingly. However, the negative charge and 
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hydrophobic nature of PLGA limit its interaction with the negatively charged DNA. Cationic surface 
modification of PLGA micro/nanoparticles using polycations such as PEI and chitosan can overcome 
this problem and allow efficient nucleic acids delivery [161–164]. This strategy has also been applied 
to the delivery of DNA vaccines. Oster et al. first employed the use of micro-particles consisting 
PLGA and PEI as DNA vaccine carrier for injection [165]. Later on, Wang et al. reported the use of 
chitosan coated PLGA nanoparticles to deliver plasmid DNA encoding FMDV (foot-and-mouth 
disease virus) capsid protein together with IL-6 as mucosal adjuvant for intranasal vaccination [166]. 
Chitosan coated PLGA nanoparticles were first prepared by emulsion-diffusion-evaporation  
technique [167], followed by the incorporation of plasmid DNA to the nanoparticles by simple 
complexing. The samples were then freeze-dried with mannitol before use. After intranasal 
administration in guinea pigs and rats, both cellular and humoral immune responses were detected.  
IL-6 was also found to be an effective mucosal adjuvant which significantly enhanced mucosal and 
systemic immune responses. More importantly, the vaccines could offer some immune protection to 
animals against FMDV challenge. 
5.3. Liposomes 
Liposomes are vesicles comprised of phospholipid bilayers. They have been extensively investigated 
for delivering DNA into mammalian cells as well as vaccine adjuvants. The duo functions make them 
an excellent carrier system for DNA vaccine [168–171]. For DNA delivery, the negatively charged 
plasmid DNA can be absorbed to the surface of cationic liposomes through electrostatic interaction to 
form complexes. Alternatively, DNA can be encapsulated in the aqueous core of the cationic, non-ionic 
or anionic liposomes. In general, transfection efficiency of cationic liposomes is superior to their non-ionic 
or anionic counterparts [172], whereas anionic liposomes provided enhanced antibody responses [171]. 
Surfaces of the liposomes can be decorated with targeting ligands or antigenic components to improve 
the immune response in vaccine formulation [173]. 
Currently, there are at least two approved liposomal vaccine formulations on the market for antigen 
delivery, including Inflexal® V (influenza vaccine) and Epaxal® (hepatitis A vaccine). Both formulations 
employed the virosomes technology (Figure 4), in which the viral proteins are bound to the surface of 
a liposome in an array, similar to what is seen on viral particles [171]. The idea is to create a safe  
viral-like particle that can induce strong protective immune response. Similar technology could be 
applied to DNA vaccines to improve immunogenicity. In fact, liposomes on their own could elicit 
immune response even in the absence of other antigens. It has been demonstrated by Lay et al. that 
DOTIM (octadecenoyloxy-ethyl-heptadecenyl-3-hydroxyethyl imidazolinium chloride)/cholesterol 
cationic liposome-DNA complexes (JVRS-100), in which an empty plasmid DNA vector was 
incorporated, were able to induce high levels of antibody and T cell immunity in mice and non-human 
primates [174]. Since lipid composition, particle size, surface charge and DNA entrapment efficiency 
of the liposomes can affect their immunogenicity and potency, these parameters must be carefully 
characterized and controlled. The major limitation of liposome as DNA vaccine carrier is long-term 
stability, as lyophilization of liposomes may not be always possible [171]. 
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Figure 4. Structure of virosome. The surface of a liposome is decorated with viral surface 
proteins such as neuraminidase (NA), hemagglutinin (HA) and other antigens. 
 
A number of studies described the use of liposomes as DNA vaccine carrier for intranasal 
administration. D’Souza et al. reported the use of a cationic and neutral co-lipid formulation,  
GAP-DLRIE:DOPE (aminopropyl-dimethyl-bis-dodecyloxy-propanaminium bromide-dioleoylphosphatidyl- 
ethanolmine) as a carrier of DNA vaccine against TB for intranasal administration [175]. Plasmid 
DNA encoding Ag85A was complexed with the lipids. Following intranasal immunization in mice, 
naked DNA was completely ineffective, probably due to the degradation of the DNA by mucosal 
nuclease. The lipid-DNA formulation was capable of inducing a weak cell-mediated immune response, 
and no humoral immune response was detected. The co-lipid intranasal formulation was compared 
with another cationic lipid formulation, Vaxfectin, which was used for intramuscular administration.  
It was found that the intramuscular formulation was able to induce a better immune response. 
However, combining intranasal and intramuscular administrations resulted in stronger immune 
responses in the lungs. Considerable improvement is needed to further develop the formulation for 
intranasal use. 
Rosada et al. developed another liposome-based formulation of DNA vaccines against TB [176]. 
The non-toxic, cationic liposome, EPC/DOPE/DOTAP (Egg phosphatidylcholine/1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine/1,2-dioleoyl-3-trimethylammonium-propane) was used. Plasmid DNA 
encoding the 65 kDa mycobacterial hsp65 was either entrapped inside or complexed with the cationic 
liposomes, and the intramuscular and intranasal routes of administration were compared in mice.  
When administered intramuscularly, both liposomal formulations were ineffective in preventing 
tuberculosis infection in mice even after two doses. On the contrary, the complexed liposomal 
formulation of DNA vaccine was able to offer protection against infection even after a single dose, 
with a significant reduction of colony forming unit (CFU) in lungs after the immunized mice were 
challenged with Mycobacterium tuberculosis. However, four doses of intranasal administration of 
naked DNA vaccines failed to offer any protection. The authors reasoned that the intranasal 
vaccination enhance the immune response by stimulating the mucosal immunity, but the naked DNA 
failed to cross the mucosal barriers in the nasal cavity, demonstrating the importance with the use of 
delivery carrier for intranasal DNA vaccination. 
Apart from TB vaccine, there are studies that reported the use of liposome to deliver influenza  
DNA vaccine [177,178]. Cationic liposomes DODAC/DOPE/PEG (1,2-dioleoyl-sn-glycero-3-
Antigen
Neuraminidase 
(NA)
Hemagglutinin 
(HA)
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phosphoethanolmine/dioleylphosphatidylethanolamine/polyethylene glycol) were used to encapsulate 
plasmid DNA encoding influenza virus HA. After intranasal immunization in mice, the liposome 
system was effective at eliciting both IgG and IgA humoral responses systemically. Local IgA level 
was enhanced. Cell-mediated immune response was also successfully induced. In addition, the immunized 
mice were able to withstand a lethal challenge of influenza virus. On the other hand, intramuscular 
immunization of the same system enhanced IgG level only with no effect on IgA level either locally  
or systemically. Intranasal administration of naked DNA failed to induce antibody response.  
The promising results demonstrated the potential of the intranasal liposomal DNA vaccine system. 
To improve the DNA vaccine delivery efficiency of liposomes for intranasal administration, Khatri et al. 
modified the surface of liposomes by coating with glycol chitosan [173]. The major function of glycol 
chitosan is to provide mucoadhesive and immune stimulating property [179]. In the study, cationic 
liposomes, PC/DOPE/Chol (Phosphatidylcholine/dioleylphosphatidylethanolamine/cholesterol) were 
used to entrap plasmid encoding the S region of hepatitis B antigen, and the glycol chitosan was 
adsorbed on the liposome surfaces through electrostatic interaction and hydrogen bonding. Following 
intranasal administration in mice, the surface modified liposomes could elicit both humoral mucosal 
and cell-mediated immune responses which were better than the uncoated liposomes. Such system has 
the potential to be exploited for intranasal DNA vaccine of respiratory infectious diseases. 
A number of studies have already demonstrated the potential of liposomal DNA vaccine system for 
intranasal administration, and some could offer considerable immune protection against respiratory 
infections in animals. However, the lipid composition of different liposomal systems varied greatly,  
and currently there is a lack of knowledge of how the composition may affect the immune response. 
To enable the utilization of liposomal DNA vaccine for clinical application and approval, a better 
understanding of how these factors govern the efficacy and immunity of the liposomal delivery system 
must first be sought. 
5.4. Mucosal Adjuvants 
To further enhance the immune responses of the DNA vaccines, adjuvants are included in the 
formulation in many studies. Adjuvants are generally defined as agents that could enhance the immune 
response of the vaccinated subjects to an antigen. In DNA vaccine, since the delivery of DNA is a major 
hurdle, DNA carrier system using bacterial, viral or non-viral vectors, as well as the cell specific targeting 
ligands, which are discussed above, are also considered as DNA vaccine adjuvants. The summary of 
DNA vaccine adjuvants being investigated are shown in Table 2. In this section, proteins and other 
macromolecules with immunopotentiating properties but are not directly involved in the delivery of 
DNA are discussed, especially those that are commonly employed for intranasal vaccination. 
Enterotoxins are protein exotoxin released by pathogens that infect the gut. Enterotoxin-based 
mucosal adjuvants are the most potent and well-established strategy for the induction of both mucosal 
and systemic immunity to co-administered protein antigens [180]. Heat-labile enterotoxin (LT) from  
E. coli and cholera enterotoxin (CT) are very potent adjuvants but they are too toxic to be used in 
human. Therefore, detoxified mutants of enterotoxins have been produced by site-directed mutagenesis 
and they are extensively investigated as adjuvants for mucosal vaccine including intranasal vaccine. 
Intranasal antigen immunization with LT mutant adjuvants can provide effective protection against 
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infectious diseases in animals [181–185]. It is suggested that the LT mutant adjuvants could induce 
potent cytotoxic T lymphocyte responses. The mechanism of action is believed to arise from enhanced 
permeation of antigens across epithelial barriers and a marked increase in antigen presentation by 
APCs [66]. Mutants of CT have also showed strong adjuvant activity [73,186,187], and could retain 
good adjuvant function when administered intranasally [73]. It is expected that LT mutants and CT 
mutants have similar mechanisms of adjuvant activities [58]. The major concern with the intranasal 
administration of mutant LT or CT is that these toxin derivatives may gain access into the central 
nervous system through the olfactory nerve. It has been reported that both native and mutant LT used 
as adjuvants were associated with the development of Bell’s palsy following intranasal delivery in 
humans [70,71,188]. The risk of enterotoxin as mucosal adjuvant for intranasal administration is already 
discussed in Section 3.4. 
Table 2. Summary of mucosal adjuvants for DNA vaccine. 
Types Examples 
Proposed Target or  
Mechanisms of Action 
Reference 
Enterotoxins and  
toxin-based derivatives 
Mutants of heat-labile 
enterotoxin and cholera toxin 
Increase antigen presentation 
by APCs 
[187,189,190] 
LPS derivatives MLA TLR4 [191] 
Cytokines and  
chemokines 
IL-2, IL-6, IL-7, IL-12,  
IL-15, GM-CSF, MCP-1, 
MIP-1α, RANTES 
T cells stimulation  
Recruit and activate APCs 
[192–206] 
Oligonucleotides CpG motifs TLR9 [21] 
Targeting ligands Flt3 ligand DEC-205 antibody 
protein sigma-1 
APC targeting DC targeting 
M cell targeting 
[65,120,122, 
129,207,208] 
Polymers PEI Improve DNA delivery [146–148,209] 
PLGA Improve DNA delivery [132–134,166, 
167,210] 
Chitosan Improve DNA delivery, 
mucoadhesion and 
immunostimulating effect 
[110,155,157, 
158,163,211] 
Liposomes DOPE/DOTAP/PC; 
DOPE/PC/Chol 
Improve DNA delivery plus 
immunostimulating effect 
[175,176, 
212–215] 
Abbreviations: LPS, lipopolysaccharide; MLA, monophosphoryl lipid A; GM-CSF, granulocyte-macrophage  
colony-stimulating factor; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory 
protein-1α; APCs, antigen presenting cells. 
Lipopolysaccharides (LPS) are the major component of the outer membrane of Gram-negative 
bacteria, and could elicit strong immune response. However, they are also highly toxic. In order to 
make them safe and suitable as vaccine adjuvants, LPS derivatives are produced to reduce the 
endotoxic effect but to retain their immunostimulatory function. Monophosphoryl lipid A (MPL) is 
one example of LPS derivative that is investigated as vaccine adjuvant. MPL is prepared by removal of 
a phosphate and fatty acid group from the lipid A of Salmonella minnesola. MPL is thought to interact 
with Toll-like receptor 4 (TLR-4) on APCs. It has been demonstrated that MPL could activate 
macrophages, increase their cytokine secretion and hence immune response [216–220]. Regarding 
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safety, MPL appears to retain the immunogenic activity of LPS but with significantly reduced  
toxicity [221]. MPL has been extensively evaluated in the clinic as adjuvants for various diseases 
including infectious diseases with an acceptable profile of adverse effects [182]. MPL has been used 
successfully as a mucosal adjuvant when formulated with liposomes or virosomes for intranasal 
administration in animals [222–224]. 
Cytokines are small proteins that are important in regulating immunological response by recruiting 
and stimulating T cells, or by directly acting on infected cells. They have potential to be natural adjuvants 
for DNA vaccines [225]. Cytokines that have been evaluated as possible DNA or intranasal vaccine 
adjuvants include IL-1, IL-2, IL-6, IL-12, IL-15 and GM-CSF [205,206,226,227]. In particular,  
IL-12 is found to be an effective mucosal adjuvant [228,229]. Lynch et al. demonstrated that intranasal 
administration of pneumococcal polysaccharide conjugate vaccine in the presence of IL-12 was able to 
enhance systemic and mucosal immune responses to pneumococci in mice [228]. However, cytokines 
have short half-life in vivo and poor stability. They are also expensive and are associated with dose 
related toxicity. Therefore, these molecules may not be suitable for use as adjuvants in vaccines 
designed to protect against infectious diseases [182]. Nevertheless, intranasal administration of IL-12 
induced less toxicity than parenteral administration [230]. Alternatively, cytokines can be expressed from 
plasmid DNA to allow long-lasting expression in vivo and to reduce the cost of production [196,198]. 
6. Concluding Remarks 
With the emergence of new or antimicrobial-resistant bacteria and viruses, and the ease of 
transmission, especially the respiratory pathogens, respiratory infections are becoming serious threats 
to human health. Safe and effective vaccines are important to safeguard public health. Intranasal DNA 
vaccination appears to be a promising non-invasive approach to provide protection against various 
infectious diseases. Evidence shows that intranasal DNA vaccine could elicit strong and long-lasting 
humoral as well as cell-mediated immune responses in many animal models. DNA vaccines are 
already successfully used in veterinary products for protection against infections, but their 
immunogenicity needs to be further enhanced to make them suitable for human use. Improving DNA 
delivery and formulation is one of the several strategies to enhance the immune response. Various 
studies have demonstrated that significant improvement of immune response that could be achieved by 
the employment of DNA carrier system, or to target the DNA vaccines to APCs. DNA vaccines 
generally have good safety profile, but the potential toxicity associated with DNA delivery systems, 
especially when they are used at high concentration, must not be neglected. DNA vaccines may 
circumvent many problems associated with conventional vaccines such as high costs of protein vaccine 
purification and bacterial/viral inactivated or attenuated process, the incorrect folding of antigen and 
viral mutation risk, thereby offering a safer alternative to benefit humans. In addition, mass 
manufacture of DNA vaccine is easier and faster, and DNA product is usually highly stable. Once an 
effective intranasal DNA vaccine delivery system is identified and optimized, a delivery technology 
platform could be established to allow the development of DNA vaccine formulations for different 
infectious diseases in the future. 
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